Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Tokyo  >  ONO PHARMACEUTICAL CO., LTD.    4528   JP3197600004

SummaryChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

ONO PHARMACEUTICAL CO., LTD. : Voluntary adoption of International Financial Reporting Standards (IFRS)(64.9KB)

share with twitter share with LinkedIn share with facebook
share via e-mail
0
05/13/2013 | 01:15pm CEST

May 13, 2013
ONO PHARMACEUTICAL CO., LTD. Corporate Communications
TEL: +81-6-6263-5670

Voluntary adoption of International Financial Reporting Standards (IFRS)

Ono Pharmaceutical Co., Ltd. (Chuo-ku, Osaka, President: Gyo Sagara) resolved at the meeting of Board of Directors held today that IFRS is to be adopted to its group's consolidated financial reports and consolidated calculation documents ending on March 31st, 2014. Its financial reports and documents used to be based on Japan Generally Accepted Accounting Principles (Japan GAAP).
Our group has been facilitating business development such as research and development and licensing activities globally in the U.S.A, Europe and Asian regions as well as in Japan. Additionally foreign investors account for about 30 % of the total shareholders as of March 31st,
2013, which has shown large proportion of foreign investors from the past. With these situations considered, we have decided to voluntarily adopt IFRS to disclose financial information based on international standards, improve comparability and enhance convenience of stakeholders
including shareholders, investors and business partners.
Ref: <Schedule of disclosure of financial information in association with the change of accounting standards>

May 2013

Flash Report and consolidated calculation document ending on

March 31st, 2013

Japan GAAP

June 2013

Annual Report ending on March 31st, 2013

Japan GAAP

Financial information on 1Q to 3Q ending on March 31st, 2014

Japan GAAP

May 2014

Flash Report and consolidated calculation document ending on

March 31st, 2014

IFRS

June 2014

Annual Report ending on March 31st, 2014

IFRS

Consolidated Financial Forecast in Fiscal Year ended March 31, 2014 (FY2013) under IFRS

Table below shows trial IFRS calculation of the consolidated forecast for the fiscal year ending March 31, 2014, disclosed today.

(Billion JPY)

IFRS (1)

J-GAAP (2)

Difference ((1) - (2))

Net sales

146.3

148.3

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ONO PHARMACEUTICAL CO., LT
09/20 ONO PHARMACEUTICAL : Opdivo® (Nivolumab) Intravenous Infusion Approved for Expan..
09/19 ONO PHARMACEUTICAL : Opdivo® (Nivolumab) Intravenous Infusion Approved for Expan..
09/14 ONO PHARMACEUTICAL : Array BioPharma Announces FDA Acceptance for Review of Bini..
09/13 ONO PHARMACEUTICAL : Phase 3 COLUMBUS Part 2 Results in BRAF-Mutant Melanoma Pre..
09/13 ONO PHARMACEUTICAL : Phase 3 BEACON CRC Safety Lead-In Results in BRAF-Mutant Co..
09/12 EISAI : Conclusion of development collaboration agreement for lenvima and opdivo..
09/12 ONO PHARMACEUTICAL : Opdivo Plus Yervoy Combination Demonstrated Superior Overal..
09/11 ONO PHARMACEUTICAL : Opdivo (nivolumab) Demonstrates Superior Recurrence-Free Su..
09/11 ONO PHARMACEUTICAL : Two Pivotal Opdivo (nivolumab) Trials Show Three-Year Survi..
09/09 EISAI : Conclusion of Development Collaboration Agreement for Lenvima (Lenvatini..
More news
News from SeekingAlpha
06/22 Only Bristol Bucks Big Pharma's Drive For External Reliance
06/02 3 THINGS IN BIOTECH YOU SHOULD LEARN : June 2, 2017
05/31 Array out-licenses binimetinib and encorafenib to Ono Pharma for Japan and So..
05/10 BRISTOL-MYERS SQUIBB : A Deep Dive Finds Some Pearls
01/23 Bristol Catches A Break At Last
Financials ( JPY)
Sales 2018 251 B
EBIT 2018 -
Net income 2018 38 761 M
Finance 2018 134 B
Yield 2018 1,93%
P/E ratio 2018 33,22
P/E ratio 2019 26,90
EV / Sales 2018 5,15x
EV / Sales 2019 4,71x
Capitalization 1 425 B
Chart ONO PHARMACEUTICAL CO., LT
Duration : Period :
ONO PHARMACEUTICAL CO., LT Technical Analysis Chart | 4528 | JP3197600004 | 4-Traders
Technical analysis trends ONO PHARMACEUTICAL CO., LT
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 15
Average target price 2 673  JPY
Spread / Average Target 11%
EPS Revisions
Managers
NameTitle
Gyo Sagara President & Representative Director
Shozo Matsuoka Executive Officer & Manager-Medical Affairs
Kazuhito Kawabata Director & Managing Executive Officer
Hiroshi Awata Director, EVP & General Manager-Development
Isao Ono Director & Managing Executive Officer
Sector and Competitors